Crosstalk between TGF-β signaling and the microRNA machinery

Chang, 2002, Genetic analysis of the mammalian transforming growth factor-beta superfamily, Endocr. Rev., 23, 787, 10.1210/er.2002-0003 Ikushima, 2010, Cellular context-dependent “colors” of transforming growth factor-beta signaling, Cancer Sci., 101, 306, 10.1111/j.1349-7006.2009.01441.x Nassiri, 2011, Endoglin (CD105): a review of its role in angiogenesis and tumor diagnosis, progression and therapy, Anticancer Res., 31, 2283 Pérez-Gómez, 2010, The role of the TGF-β coreceptor endoglin in cancer, Sci. World J., 10, 2367, 10.1100/tsw.2010.230 Petrocca, 2008, E2F1-regulated microRNAs impair TGFβ-dependent cell-cycle arrest and apoptosis in gastric cancer, Cancer Cell, 13, 272, 10.1016/j.ccr.2008.02.013 Kalluri, 2009, The basics of epithelial–mesenchymal transition, J. Clin. Invest., 119, 1420, 10.1172/JCI39104 Brabletz, 2005, Invasion and metastasis in colorectal cancer: epithelial–mesenchymal transition, mesenchymal–epithelial transition, stem cells and beta-catenin, Cells Tissues Organs, 179, 56, 10.1159/000084509 Adorno, 2009, A mutant-p53/Smad complex opposes p63 to empower TGFβ-induced metastasis, Cell, 137, 87, 10.1016/j.cell.2009.01.039 Oft, 1996, TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells, Genes Dev., 10, 2462, 10.1101/gad.10.19.2462 Bruna, 2007, High TGFβ-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene, Cancer Cell, 11, 147, 10.1016/j.ccr.2006.11.023 Butz, 2011, MicroRNA profile indicates downregulation of the TGFβ pathway in sporadic non-functioning pituitary adenomas, Pituitary, 14, 112, 10.1007/s11102-010-0268-x Lagos-Quintana, 2001, Identification of novel genes coding for small expressed RNAs, Science, 294, 853, 10.1126/science.1064921 Place, 2008, MicroRNA-373 induces expression of genes with complementary promoter sequences, Proc. Natl. Acad. Sci. U.S.A., 105, 1608, 10.1073/pnas.0707594105 Orom, 2008, MicroRNA-10a binds the 5′UTR of ribosomal protein mRNAs and enhances their translation, Mol. Cell, 30, 460, 10.1016/j.molcel.2008.05.001 Zhang, 2010, MiR-145, a new regulator of the DNA fragmentation factor-45 (DFF45)-mediated apoptotic network, Mol. Cancer, 9, 211, 10.1186/1476-4598-9-211 Huang, 2010, MicroRNA-181a modulates gene expression of zinc finger family members by directly targeting their coding regions, Nucleic Acids Res., 38, 7211, 10.1093/nar/gkq564 Chen, 2006, Natural selection on human miRNA binding sites inferred from SNP data, Nat. Genet., 38, 1452, 10.1038/ng1910 Lewis, 2005, Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets, Cell, 120, 15, 10.1016/j.cell.2004.12.035 Mattick, 2005, Small regulatory RNAs in mammals, Hum. Mol. Genet., 14, R121, 10.1093/hmg/ddi101 Sayed, 2011, MicroRNAs in development and disease, Physiol. Rev., 91, 827, 10.1152/physrev.00006.2010 Lima, 2011, MicroRNA regulation of core apoptosis pathways in cancer, Eur. J. Cancer, 47, 163, 10.1016/j.ejca.2010.11.005 Davis-Dusenbery, 2010, Mechanisms of control of microRNA biogenesis, J. Biochem., 148, 381 Braun, 2010, Downregulation of microRNAs directs the EMT and invasive potential of anaplastic thyroid carcinomas, Oncogene, 29, 4237, 10.1038/onc.2010.169 Zhong, 2010, Targeting Smad4 links microRNA-146a to the TGF-beta pathway during retinoid acid induction in acute promyelocytic leukemia cell line, Int. J. Hematol., 92, 129, 10.1007/s12185-010-0626-5 Tzur, 2009, Comprehensive gene and microRNA expression profiling reveals a role for microRNAs in human liver development, PLoS ONE, 4, e7511, 10.1371/journal.pone.0007511 Rogler, 2009, MicroRNA-23b cluster microRNAs regulate transforming growth factor-beta/bone morphogenetic protein signaling and liver stem cell differentiation by targeting Smads, Hepatology, 50, 575, 10.1002/hep.22982 Shan, 2009, Downregulation of miR-133 and miR-590 contributes to nicotine-induced atrial remodelling in canines, Cardiovasc. Res., 83, 465, 10.1093/cvr/cvp130 Marquez, 2010, Correlation between microRNA expression levels and clinical parameters associated with chronic hepatitis C viral infection in humans, Lab. Invest., 90, 1727, 10.1038/labinvest.2010.126 Liu, 2010, miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis, J. Exp. Med., 207, 1589, 10.1084/jem.20100035 Leeper, 2010, MicroRNA-26a is a novel regulator of vascular smooth muscle cell function, J. Cell Physiol., 226, 1035, 10.1002/jcp.22422 Wang, 2011, miR-200a prevents renal fibrogenesis through repression of TGF-β2 expression, Diabetes, 60, 280, 10.2337/db10-0892 Pais, 2010, Analyzing mRNA expression identifies Smad3 as a microRNA-140 target regulated only at protein level, RNA, 16, 489, 10.1261/rna.1701210 Fontana, 2008, Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM, PLoS ONE, 3, e2236, 10.1371/journal.pone.0002236 Mestdagh, 2010, The miR-17-92 microRNA cluster regulates multiple components of the TGF-β pathway in neuroblastoma, Mol. Cell, 40, 762, 10.1016/j.molcel.2010.11.038 Petrocca, 2008, Emerging role of miR-106b-25/miR-17-92 clusters in the control of transforming growth factor beta signaling, Cancer Res., 68, 8191, 10.1158/0008-5472.CAN-08-1768 Wang, 2010, MicroRNA-204/211 alters epithelial physiology, FASEB J., 24, 1552, 10.1096/fj.08-125856 Casas, 2011, Snail2 is an essential mediator of Twist1-induced epithelial mesenchymal transition and metastasis, Cancer Res., 71, 245, 10.1158/0008-5472.CAN-10-2330 Reeves, 1990, The A-T-DNA-binding domain of mammalian high mobility group I chromosomal proteins. A novel peptide motif for recognizing DNA structure, J. Biol. Chem., 265, 8573, 10.1016/S0021-9258(19)38926-4 Sgarra, 2004, Nuclear phosphoproteins HMGA and their relationship with chromatin structure and cancer, FEBS Lett., 574, 1, 10.1016/j.febslet.2004.08.013 Thuault, 2006, Transforming growth factor-beta employs HMGA2 to elicit epithelial–mesenchymal transition, J. Cell Biol., 174, 175, 10.1083/jcb.200512110 Thuault, 2008, HMGA2 and Smads co-regulate SNAIL1 expression during induction of epithelial-to-mesenchymal transition, J. Biol. Chem., 283, 33437, 10.1074/jbc.M802016200 Mahajan, 2010, HMGA2: a biomarker significantly overexpressed in high-grade ovarian serous carcinoma, Mod. Pathol., 23, 673, 10.1038/modpathol.2010.49 Mu, 2010, Correlation of overexpression of HMGA1 and HMGA2 with poor tumor differentiation, invasion, and proliferation associated with let-7 down-regulation in retinoblastomas, Hum. Pathol., 41, 493, 10.1016/j.humpath.2009.08.022 Shi, 2009, Let-7 repression leads to HMGA2 overexpression in uterine leiomyosarcoma, J. Cell. Mol. Med., 13, 3898, 10.1111/j.1582-4934.2008.00541.x Rahman, 2009, Frequent overexpression of HMGA1 and 2 in gastroenteropancreatic neuroendocrine tumours and its relationship to let-7 downregulation, Br. J. Cancer, 100, 501, 10.1038/sj.bjc.6604883 Qian, 2009, Overexpression of HMGA2 relates to reduction of the let-7 and its relationship to clinicopathological features in pituitary adenomas, Mod. Pathol., 22, 431, 10.1038/modpathol.2008.202 Korpal, 2008, The miR-200 family inhibits epithelial–mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2, J. Biol. Chem., 283, 14910, 10.1074/jbc.C800074200 Park, 2008, The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2, Genes Dev., 22, 894, 10.1101/gad.1640608 Gregory, 2008, The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1, Nat. Cell Biol., 10, 593, 10.1038/ncb1722 Burk, 2008, A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells, EMBO Rep., 9, 582, 10.1038/embor.2008.74 Pandit, 2010, Inhibition and role of let-7d in idiopathic pulmonary fibrosis, Am. J. Respir. Crit. Care Med., 182, 220, 10.1164/rccm.200911-1698OC Sun, 2008, Transforming growth factor-beta-regulated miR-24 promotes skeletal muscle differentiation, Nucleic Acids Res., 36, 2690, 10.1093/nar/gkn032 Qian, 2009, High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1, Breast Cancer Res. Treat., 117, 131, 10.1007/s10549-008-0219-7 Godwin, 2010, Identification of a microRNA signature of renal ischemia reperfusion injury, Proc. Natl. Acad. Sci. U.S.A., 107, 14339, 10.1073/pnas.0912701107 Yu, 2010, Context-dependent bidirectional regulation of the mutS homolog 2 by transforming growth factor β contributes to chemoresistance in breast cancer cells, Mol. Cancer Res., 8, 1633, 10.1158/1541-7786.MCR-10-0362 Kim, 2009, MiR-21 regulates adipogenic differentiation through the modulation of TGF-β signaling in mesenchymal stem cells derived from human adipose tissue, Stem Cells, 27, 3093, 10.1002/stem.235 Pan, 2010, microRNA 21: response to hormonal therapies and regulatory function in leiomyoma, transformed leiomyoma and leiomyosarcoma cells, Mol. Hum. Reprod., 16, 215, 10.1093/molehr/gap093 Papagiannakopoulos, 2008, MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells, Cancer Res., 68, 8164, 10.1158/0008-5472.CAN-08-1305 Zavadil, 2007, Transforming growth factor-beta and microRNA:mRNA regulatory networks in epithelial plasticity, Cells Tissues Organs, 185, 157, 10.1159/000101316 Mizuno, 2009, miR-210 promotes osteoblastic differentiation through inhibition of AcvR1b, FEBS Lett., 583, 2263, 10.1016/j.febslet.2009.06.006 Chung, 2010, miR-192 mediates TGF-beta/Smad3-driven renal fibrosis, J. Am. Soc. Nephrol., 21, 1317, 10.1681/ASN.2010020134 Tili, 2010, GAM/ZFp/ZNF512B is central to a gene sensor circuitry involving cell-cycle regulators, TGFβ effectors, Drosha and microRNAs with opposite oncogenic potentials, Nucleic Acids Res., 38, 7673, 10.1093/nar/gkq637 Dews, 2010, The myc-miR-17∼92 axis blunts TGFβ signaling and production of multiple TGFβ-dependent antiangiogenic factors, Cancer Res., 70, 8233, 10.1158/0008-5472.CAN-10-2412 Ventura, 2009, MicroRNAs and cancer: short RNAs go a long way, Cell, 136, 586, 10.1016/j.cell.2009.02.005 Gal, 2008, MIR-451 and Imatinib mesylate inhibit tumor growth of glioblastoma stem cells, Biochem. Biophys. Res. Commun., 376, 86, 10.1016/j.bbrc.2008.08.107 Huang, 2008, Upregulation of miR-23a approximately 27a approximately 24 decreases transforming growth factor-β-induced tumor-suppressive activities in human hepatocellular carcinoma cells, Int. J. Cancer, 123, 972, 10.1002/ijc.23580 Kato, 2010, Post-transcriptional up-regulation of Tsc-22 by Ybx1, a target of miR-216a, mediates TGF-β-induced collagen expression in kidney cells, J. Biol. Chem., 285, 34004, 10.1074/jbc.M110.165027 Kong, 2008, MicroRNA-155 is regulated by the transforming growth factor β/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA, Mol. Cell. Biol., 28, 6773, 10.1128/MCB.00941-08 Pottier, 2009, Identification of keratinocyte growth factor as a target of microRNA-155 in lung fibroblasts: implication in epithelial–mesenchymal interactions, PLoS ONE, 4, e6718, 10.1371/journal.pone.0006718 Louafi, 2010, Microrna-155 (miR-155) targets SMAD2 and modulates the response of macrophages to transforming growth factor-β (TGF-β), J. Biol. Chem., 285, 41328, 10.1074/jbc.M110.146852 Yin, 2008, MicroRNA-155 is an Epstein-Barr virus-induced gene that modulates Epstein-Barr virus-regulated gene expression pathways, J. Virol., 82, 5295, 10.1128/JVI.02380-07 Rai, 2010, Targeting of SMAD5 links microRNA-155 to the TGF-β pathway and lymphomagenesis, Proc. Natl. Acad. Sci. U.S.A., 107, 3111, 10.1073/pnas.0910667107 Yin, 2010, MicroRNA miR-155 inhibits bone morphogenetic protein (BMP) signaling and BMP-mediated Epstein-Barr virus reactivation, J. Virol., 84, 6318, 10.1128/JVI.00635-10 Krol, 2010, The widespread regulation of microRNA biogenesis, function and decay, Nat. Rev. Genet., 11, 597, 10.1038/nrg2843 Davis, 2008, SMAD proteins control DROSHA-mediated microRNA maturation, Nature, 454, 56, 10.1038/nature07086 Davis, 2010, Smad proteins bind a conserved RNA sequence to promote microRNA maturation by Drosha, Mol. Cell, 39, 373, 10.1016/j.molcel.2010.07.011 Fuentealba, 2007, Integrating patterning signals: Wnt/GSK3 regulates the duration of the BMP/Smad1 signal, Cell, 131, 980, 10.1016/j.cell.2007.09.027 Kretzschmar, 1997, Opposing BMP and EGF signalling pathways converge on the TGF-beta family mediator Smad1, Nature, 389, 618, 10.1038/39348 Suzuki, 2009, Modulation of microRNA processing by p53, Nature, 460, 529, 10.1038/nature08199 Nagaraj, 2010, Targeting the transforming growth factor-β signaling pathway in human cancer, Expert Opin. Investig. Drugs, 19, 77, 10.1517/13543780903382609 Korpal, 2010, Targeting the transforming growth factor-β signalling pathway in metastatic cancer, Eur. J. Cancer, 46, 1232, 10.1016/j.ejca.2010.02.040 Pennison, 2007, Targeting transforming growth factor-beta signaling, Curr. Opin. Oncol., 19, 579, 10.1097/CCO.0b013e3282f0ad0e Hoefer, 1995, Anti-(transforming growth factor β) antibodies with predefined specificity inhibit metastasis of highly tumorigenic human xenotransplants in nu/nu mice, Cancer Immunol. Immunother., 41, 302, 10.1007/BF01517218 Benigni, 2003, Add-on anti-TGF-β antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat, J. Am. Soc. Nephrol., 14, 1816, 10.1097/01.ASN.0000074238.61967.B7 Arteaga, 1993, Anti-transforming growth factor (TGF)-β antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-β interactions in human breast cancer progression, J. Clin. Invest., 92, 2569, 10.1172/JCI116871 Lahn, 2005, TGF-β inhibitors for the treatment of cancer, Expert Opin. Investig. Drugs, 14, 629, 10.1517/13543784.14.6.629 Mead, 2003, Evaluation of anti-TGF-β2 antibody as a new postoperative anti-scarring agent in glaucoma surgery, Invest. Ophthalmol. Vis. Sci., 44, 3394, 10.1167/iovs.02-0978 Zhao, 2002, Suppression of in vivo tumorigenicity of rat hepatoma cell line KDH-8 cells by soluble TGF-beta receptor type II, Cancer Immunol. Immunother., 51, 381, 10.1007/s00262-002-0290-6 Muraoka, 2002, Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases, J. Clin. Invest., 109, 1551, 10.1172/JCI0215234 Bandyopadhyay, 2002, Extracellular domain of TGFβ type III receptor inhibits angiogenesis and tumor growth in human cancer cells, Oncogene, 21, 3541, 10.1038/sj.onc.1205439 Fakhrai, 1996, Eradication of established intracranial rat gliomas by transforming growth factor β antisense gene therapy, Proc. Natl. Acad. Sci. U.S.A., 93, 2909, 10.1073/pnas.93.7.2909 Wu, 2001, Comparative analysis of IFN-γ B7.1 and antisense TGF-β gene transfer on the tumorigenicity of a poorly immunogenic metastatic mammary carcinoma, Cancer Immunol. Immunother., 50, 229, 10.1007/s002620100197 Bogdahn, 2004, Specific therapy for high-grade glioma by convection-enhanced delivery of the TGF-β2 specific antisense oligonucleotide AP 12009, J. Clin. Oncol., 22, 1514, 10.1200/jco.2004.22.14_suppl.1514 Stauder, 2004, TGF-β2 suppression by the antisense oligonucleotide AP 12009 as treatment for pancreatic cancer: preclinical efficacy data, J. Clin. Oncol., 22, 4106, 10.1200/jco.2004.22.14_suppl.4106 Schlingensiepen, 2004, The TGF-β1 antisense oligonucleotide AP 11014 for the treatment of non-small cell lung, colorectal and prostate cancer: preclinical studies, J. Clin. Oncol., 22, 3132, 10.1200/jco.2004.22.14_suppl.3132 Schlingensiepen, 2008, Antisense therapeutics for tumor treatment: the TGF-β2 inhibitor AP 12009 in clinical development against malignant tumors, Recent Results Cancer Res., 177, 137, 10.1007/978-3-540-71279-4_16 Saunier, 2006, TGF β inhibition for cancer therapy, Curr. Cancer Drug Targets, 6, 565, 10.2174/156800906778742460 Hau, 2009, Treatment of malignant gliomas with TGF-β2 antisense oligonucleotides, Expert Rev. Anticancer Ther., 9, 1663, 10.1586/era.09.138 Nemunaitis, 2009, Phase II trial of Belagenpumatucel-L, a TGF-β2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients, Cancer Gene Ther., 16, 620, 10.1038/cgt.2009.15 Peng, 2005, Kinetic characterization of novel pyrazole TGF-β receptor I kinase inhibitors and their blockade of the epithelial–mesenchymal transition, Biochemistry, 44, 2293, 10.1021/bi048851x Subramanian, 2004, Targeting endogenous transforming growth factor β receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1, Cancer Res., 64, 5200, 10.1158/0008-5472.CAN-04-0018 Uhl, 2004, SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo, Cancer Res., 64, 7954, 10.1158/0008-5472.CAN-04-1013 Moon, 2006, IN-1130, a novel transforming growth factor-β type I receptor kinase (ALK5) inhibitor, suppresses renal fibrosis in obstructive nephropathy, Kidney Int., 70, 1234, 10.1038/sj.ki.5001775 He, 2009, Applications of RNA interference in cancer therapeutics as a powerful tool for suppressing gene expression, Mol. Biol. Rep., 36, 2153, 10.1007/s11033-008-9429-7 Sotillo, 2011, Shielding the messenger (RNA): microRNA-based anticancer therapies, Pharmacol. Ther., 131, 18, 10.1016/j.pharmthera.2011.04.006 Zhang, 2009, Up-regulated microRNA-143 transcribed by nuclear factor κ B enhances hepatocarcinoma metastasis by repressing fibronectin expression, Hepatology, 50, 490, 10.1002/hep.23008 Trang, 2010, Regression of murine lung tumors by the let-7 microRNA, Oncogene, 29, 1580, 10.1038/onc.2009.445 Grimm, 2006, Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways, Nature, 441, 537, 10.1038/nature04791 Aagaard, 2007, RNAi therapeutics: principles, prospects and challenges, Adv. Drug Deliv. Rev., 59, 75, 10.1016/j.addr.2007.03.005 Lu, 2009, A single anti-microRNA antisense oligodeoxyribonucleotide (AMO) targeting multiple microRNAs offers an improved approach for microRNA interference, Nucleic Acids Res., 37, e24, 10.1093/nar/gkn1053 Greenberger, 2008, A RNA antagonist of hypoxia-inducible factor-1α, EZN-2968, inhibits tumor cell growth, Mol. Cancer Ther., 7, 3598, 10.1158/1535-7163.MCT-08-0510 Davis, 2010, Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles, Nature, 464, 1067, 10.1038/nature08956 Lanford, 2009, Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection, Science, 327, 198, 10.1126/science.1178178 Ebert, 2007, MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells, Nat. Methods, 4, 721, 10.1038/nmeth1079 Choi, 2007, Target protectors reveal dampening and balancing of Nodal agonist and antagonist by miR-430, Science, 318, 271, 10.1126/science.1147535 Masri, 2010, The role of microRNA-128a in regulating TGFβ signaling in letrozole-resistant breast cancer cells, Breast Cancer Res. Treat., 124, 89, 10.1007/s10549-009-0716-3 Kim, 2009, Biogenesis of small RNAs in animals, Nat. Rev. Mol. Cell Biol., 10, 126, 10.1038/nrm2632 Zhang, 2010, Regulation of mammalian microRNA expression, J. Cardiovasc. Transl. Res., 3, 197, 10.1007/s12265-010-9166-x Cai, 2004, Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs, RNA, 10, 1957, 10.1261/rna.7135204 Gregory, 2004, The microprocessor complex mediates the genesis of microRNAs, Nature, 432, 235, 10.1038/nature03120 Lund, 2004, Nuclear export of microRNA precursors, Science, 303, 95, 10.1126/science.1090599 Chendrimada, 2005, TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing, Nature, 436, 740, 10.1038/nature03868 Gregory, 2005, Human RISC couples microRNA biogenesis and posttranscriptional gene silencing, Cell, 123, 631, 10.1016/j.cell.2005.10.022 Ghildiyal, 2010, Sorting of Drosophila small silencing RNAs partitions microRNA* strands into the RNA interference pathway, RNA, 16, 43, 10.1261/rna.1972910 Khvorova, 2003, Functional siRNA and miRNAs exhibit strand bias, Cell, 115, 209, 10.1016/S0092-8674(03)00801-8 Ruby, 2007, Intronic microRNA precursors that bypass Drosha processing, Nature, 448, 83, 10.1038/nature05983 Ye, 2008, The effect of central loops in miRNA:MRE duplexes on the efficiency of miRNA-mediated gene regulation, PLoS ONE, 3, e1719, 10.1371/journal.pone.0001719 Zamore, 2000, RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals, Cell, 101, 25, 10.1016/S0092-8674(00)80620-0 Bartel, 2004, MicroRNAs: genomics, biogenesis, mechanism, and function, Cell, 116, 281, 10.1016/S0092-8674(04)00045-5 Pillai, 2005, Inhibition of translational initiation by Let-7 MicroRNA in human cells, Science, 309, 1573, 10.1126/science.1115079 Kiriakidou, 2007, An mRNA m7G cap binding-like motif within human Ago2 represses translation, Cell, 129, 1141, 10.1016/j.cell.2007.05.016 Zinovyev, 2010, Dynamical modeling of microRNA action on the protein translation process, BMC Syst. Biol., 4, 13, 10.1186/1752-0509-4-13 Martin, 2011, Post-transcriptional regulation of transforming growth factor β-1 by microRNA-744, PLoS ONE, 6, e25044, 10.1371/journal.pone.0025044 Denby, 2011, miR-21 and miR-214 are consistently modulated during renal injury in rodent models, Am. J. Pathol., 179, 661, 10.1016/j.ajpath.2011.04.021 Wang, 2010, miR-106b aberrantly expressed in a double transgenic mouse model for Alzheimer's disease targets TGF-β type II receptor, Brain Res., 1357, 166, 10.1016/j.brainres.2010.08.023 Li, 2011, Small RNA-mediated regulation of iPS cell generation, EMBO J., 30, 823, 10.1038/emboj.2011.2 Volinia, 2006, A microRNA expression signature of human solid tumors defines cancer gene targets, Proc. Natl. Acad. Sci. U.S.A., 103, 2257, 10.1073/pnas.0510565103 Lewis, 2003, Prediction of mammalian microRNA targets, Cell, 115, 787, 10.1016/S0092-8674(03)01018-3 Luzi, 2008, Osteogenic differentiation of human adipose tissue-derived stem cells is modulated by the miR-26a targeting of the SMAD1 transcription factor, J. Bone Miner. Res., 23, 287, 10.1359/jbmr.071011 Lin, 2009, miR-199a, a bone morphogenic protein 2-responsive microRNA, regulates chondrogenesis via direct targeting to Smad1, J. Biol. Chem., 284, 11326, 10.1074/jbc.M807709200 Liu, 2012, MicroRNA-146a modulates TGF-β1-induced phenotypic differentiation in human dermal fibroblasts by targeting SMAD4, Arch. Dermatol. Res., 304, 195, 10.1007/s00403-011-1178-0 Geraldo, 2012, MicroRNA miR-146b-5p regulates signal transduction of TGF-β by repressing SMAD4 in thyroid cancer, Oncogene, 31, 1910, 10.1038/onc.2011.381 Häger, 2011, MicroRNA-130a-mediated downregulation of Smad4 contributes to reduced sensitivity to TGF-β1 stimulation in granulocytic precursors, Blood, 118, 6649, 10.1182/blood-2011-03-339978 Lim, 2005, Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs, Nature, 433, 769, 10.1038/nature03315 Kim, 2011, MicroRNA-142-3p regulates TGF-β3-mediated region-dependent chondrogenesis by regulating ADAM9, Biochem. Biophys. Res. Commun., 414, 653, 10.1016/j.bbrc.2011.09.104 Yang, 2011, MicroRNA-145 regulates chondrogenic differentiation of mesenchymal stem cells by targeting Sox9, PLoS ONE, 6, e21679, 10.1371/journal.pone.0021679 Long, 2011, Transforming growth factor-β1 (TGF-β1) utilizes distinct pathways for the transcriptional activation of microRNA 143/145 in human coronary artery smooth muscle cells, J. Biol. Chem., 286, 30119, 10.1074/jbc.M111.258814 Jurkin, 2010, miR-146a is differentially expressed by myeloid dendritic cell subsets and desensitizes cells to TLR2-dependent activation, J. Immunol., 184, 4955, 10.4049/jimmunol.0903021 Dogar, 2011, Suppression of latent transforming growth factor (TGF)-β1 restores growth inhibitory TGF-β signaling through microRNAs, J. Biol. Chem., 286, 16447, 10.1074/jbc.M110.208652 Wang, 2010, TGFβ-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3, Oncogene, 29, 1787, 10.1038/onc.2009.468 Wang, 2011, Transforming growth factor-β regulates the sphere-initiating stem cell-like feature in breast cancer through miRNA-181 and ATM, Oncogene, 30, 1470, 10.1038/onc.2010.531 Kato, 2007, MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-β-induced collagen expression via inhibition of E-box repressors, Proc. Natl. Acad. Sci. U.S.A., 104, 3432, 10.1073/pnas.0611192104 Sun, 2011, Low-dose paclitaxel ameliorates fibrosis in the remnant kidney model by down-regulating miR-192, J. Pathol., 225, 364, 10.1002/path.2961 Ahn, 2011, Smad3 regulates E-cadherin via miRNA-200 pathway, Oncogene Winbanks, 2011, TGF-β regulates miR-206 and miR-29 to control myogenic differentiation through regulation of HDAC4, J. Biol. Chem., 286, 13805, 10.1074/jbc.M110.192625 Zhong, 2011, Smad3-mediated upregulation of miR-21 promotes renal fibrosis, J. Am. Soc. Nephrol., 22, 1668, 10.1681/ASN.2010111168 Kato, 2009, TGF-β activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN, Nat. Cell Biol., 11, 881, 10.1038/ncb1897 Yao, 2010, MicroRNA-224 is involved in transforming growth factor-β-mediated mouse granulosa cell proliferation and granulosa cell function by targeting Smad4, Mol. Endocrinol., 24, 540, 10.1210/me.2009-0432 Papadimitriou, 2011, Differential regulation of the two RhoA-specific GEF isoforms Net1/Net1A by TGF-β and miR-24: role in epithelial-to-mesenchymal transition, Oncogene Wang, 2012, Cardiomyocyte overexpression of miR-27b induces cardiac hypertrophy and dysfunction in mice, Cell Res., 22, 516, 10.1038/cr.2011.132 Roderburg, 2010, Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis, Hepatology, 53, 209, 10.1002/hep.23922